Researchers plan to enroll approximately 190 women aged 18 to 45 across seven European countries, including the UK, Italy, Poland, Romania, Bulgaria, the Czech Republic, and Hungary.
The company also secured additional preferential participation in future exit proceeds, though these returns depend on Lone Star first recovering its initial equity investment.
The site will continue operating as a subsidiary under the Syntagon name, maintaining its established brand presence in the pharmaceutical manufacturing sector.